Neuraxis (NRXS) vs Outset Medical (OM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Outset Medical (OM) over the past year, gaining 116.3% versus a loss of 74.1%. Neuraxis is the larger company by market cap ($85.0 million vs $76.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | OM |
|---|---|---|
| Share price | $6.77 | $4.09 |
| Market cap | $85.02M | $76.88M |
| 1-day change | -0.88% | -2.85% |
| YTD return | +49.12% | +10.24% |
| 1-year return | +116.29% | -74.13% |
| 5-year return | — | -99.44% |
| EPS (TTM) | $-0.78 | $-4.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $15.94 |
| 52-week low | $2.21 | $2.84 |
| Distance from 52-week high | -27.44% | -74.34% |
| Analyst consensus | none | buy |
| Avg. price target upside | +62.48% | +87.53% |
| Average volume | 107.27K | 158.75K |
| Shares outstanding | 12.56M | 18.80M |
| Employees | 24 | 310 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed OM by 190.4 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Healthcare · Biotechnology · 24 employees
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Healthcare · Medical Devices · 310 employees
NRXS vs OM FAQ
Which is bigger, Neuraxis or Outset Medical?
Neuraxis (NRXS) is larger, with a market capitalization of $85.02M compared with $76.88M for Outset Medical (OM).
Which stock has performed better over the past year, NRXS or OM?
NRXS returned +116.29% over the past 12 months, compared with -74.13% for OM (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and Outset Medical in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Neuraxis and Medical Devices for Outset Medical.